Heidelberg, Germany, April 26, 2017 - Apogenix AG, a biopharmaceutical company developing next-generation immuno-oncology therapeutics, announced today that the company will present at the 13th Annual PEGS (Protein Engineering Summit), UBS - Global Healthcare Conference and Sachs 3rd Annual Immuno-Oncology: BD&L and Investment Forum.
13th Annual PEGS Boston (May 1 - 5, 2017)
Venue: Seaport World Trade Center, Boston, MA, USA
Presentation on May 1, 11:20 AM: “Hexavalent Agonists Targeting Co-Stimulatory Receptors of the TNFR-Superfamily”
Presenter: Oliver Hill, Ph.D., Vice President, Molecular Biology
Presentation on May 4, 3:20 PM: “Targeting Co-Stimulatory TNF Receptors with Hexavalent TNF Receptor Agonists (HERA)”
Presenter: Harald Fricke, M.D., CMO
UBS - Global Healthcare Conference (May 22 - 24, 2017)
Venue: Grand Hyatt New York, NY, USA
Presentation on May 23, 3:30 PM: “Apogenix - Next Generation Immuno-Oncology Therapeutics”
Presenter: Thomas Hoeger, Ph.D., CEO
Sachs 3rd Annual Immuno-Oncology: BD&L and Investment Forum (June 2, 2017)
Venue: Hyatt Chicago Magnificent Mile, Chicago, IL, USA
Presentation on June 2, 10:20 AM: Panel “New Approaches to IO & Combination Therapies”
Presenter: Juergen Gamer, Ph.D., VP Business Development
About Apogenix
Apogenix is a private company developing innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of immuno-oncology drug candidates that target different tumor necrosis factor superfamily (TNFSF)-dependent signaling pathways, thereby restoring the immune response against tumors. Since its inception in 2005, Apogenix has raised more than 100 million euros in financing rounds, public grants, as well as upfront and milestone payments from licensing agreements. The company is based in Heidelberg, Germany.
Contact
Thomas Hoeger, Ph.D., CEO
Apogenix AG
Phone: +49 (6221) 58 60 80
E-Mail: contact@apogenix.com
Web: www.apogenix.com
Media Contacts
Katja Arnold, Laurie Doyle
MC Services AG
Phone: +49 (89) 210 228 0
apogenix@mc-services.eu
